Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Prevention and early detection of prostate cancer.

Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilic D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A.

Lancet Oncol. 2014 Oct;15(11):e484-92. doi: 10.1016/S1470-2045(14)70211-6. Review.

2.

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).

Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K.

EJIFCC. 2014 Apr 28;25(1):55-78. eCollection 2014 Apr.

3.

The long and winding road to FDA approval of a novel prostate cancer test: our story.

Rittenhouse H, Blase A, Shamel B, Schalken J, Groskopf J.

Clin Chem. 2013 Jan;59(1):32-4. doi: 10.1373/clinchem.2012.198739. Epub 2012 Nov 28. No abstract available.

PMID:
23193060
4.

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.

Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.

PMID:
21820580
5.

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.

Sci Transl Med. 2011 Aug 3;3(94):94ra72. doi: 10.1126/scitranslmed.3001970.

6.

PCA3: from basic molecular science to the clinical lab.

Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H.

Cancer Lett. 2011 Feb 1;301(1):1-6. doi: 10.1016/j.canlet.2010.10.019. Epub 2010 Nov 18. Review.

PMID:
21093148
7.

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J.

J Urol. 2010 Nov;184(5):1947-52. doi: 10.1016/j.juro.2010.06.098. Epub 2010 Sep 17.

PMID:
20850153
8.

Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood.

Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, Groskopf J, Rittenhouse HG, Vessella RL, Reynolds MA.

Mol Cancer. 2010 Jul 2;9:174. doi: 10.1186/1476-4598-9-174.

9.

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. doi: 10.1158/1078-0432.CCR-09-2191. Epub 2010 Feb 16.

10.

[New biomarkers and application of multivariate models for detection of prostate cancer].

Stephan C, Cammann H, Rittenhouse H, Lein M, Jentzmik F, Schrader M, Deger S, Miller K, Jung K.

Aktuelle Urol. 2009 Aug;40(4):221-30. doi: 10.1055/s-0029-1224535. Epub 2009 Jul 24. Review. German.

PMID:
19634072
11.

New markers and multivariate models for prostate cancer detection.

Stephan C, Rittenhouse H, Cammann H, Lein M, Schrader M, Deger S, Miller K, Jung K.

Anticancer Res. 2009 Jul;29(7):2589-600. Review.

12.

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP; National Academy of Clinical Biochemistry.

Clin Chem. 2008 Dec;54(12):e11-79. doi: 10.1373/clinchem.2008.105601.

PMID:
19042984
13.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
14.

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I.

J Urol. 2008 Oct;180(4):1303-8; discussion 1308. doi: 10.1016/j.juro.2008.06.038. Epub 2008 Aug 15. Erratum in: J Urol. 2009 Mar;181(3):1507.

PMID:
18707724
15.

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.

van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2008 Aug 1;68(11):1215-22. doi: 10.1002/pros.20781.

PMID:
18500693
16.

PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.

Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ.

J Urol. 2008 May;179(5):1804-9; discussion 1809-10. doi: 10.1016/j.juro.2008.01.013. Epub 2008 Mar 18.

PMID:
18353398
17.

PCA3: a molecular urine assay for predicting prostate biopsy outcome.

Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J.

J Urol. 2008 Apr;179(4):1587-92. doi: 10.1016/j.juro.2007.11.038. Epub 2008 Mar 4.

PMID:
18295257
18.

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy.

Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, Groskopf J, Vessella RL.

Clin Chim Acta. 2008 Mar;389(1-2):1-6. Epub 2007 Nov 17. Erratum in: Clin Chim Acta. 2009 Jul;405(1-2):164.

PMID:
18061575
19.

Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A.

Rev Urol. 2007 Summer;9(3):113-23.

20.

Molecular PCA3 diagnostics on prostatic fluid.

van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA.

Prostate. 2007 Jun 1;67(8):881-7.

PMID:
17440939
21.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J.

Urology. 2007 Mar;69(3):532-5.

PMID:
17382159
22.

Molecular markers for prostate cancer.

Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H.

Cancer Lett. 2007 Apr 28;249(1):5-13. Epub 2007 Feb 15. Review.

PMID:
17303324
23.

Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.

Parwani AV, Marlow C, Demarzo AM, Mikolajczyk SD, Rittenhouse HG, Veltri RW, Chan TY.

Am J Surg Pathol. 2006 Oct;30(10):1231-6.

PMID:
17001152
24.

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.

Clin Chem. 2006 Jun;52(6):1089-95. Epub 2006 Apr 20.

PMID:
16627561
25.

Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urol Oncol. 2005 Jan-Feb;23(1):16-21.

PMID:
15885578
26.

Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.

de Vries SH, Raaijmakers R, Blijenberg BG, Mikolajczyk SD, Rittenhouse HG, Schröder FH.

Urology. 2005 May;65(5):926-30.

PMID:
15882725
27.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.

J Urol. 2005 Mar;173(3):752-6.

PMID:
15711262
28.

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, Linton HJ, Evans CL, Rittenhouse HG, Partin AW.

Urology. 2004 Dec;64(6):1160-4.

PMID:
15596190
29.

Up close and personal: molecular diagnostics in oncology.

Rye PD, Rittenhouse H, Stigbrand T.

Tumour Biol. 2004 Jul-Aug;25(4):217-20.

PMID:
15557760
30.

Are multiple markers the future of prostate cancer diagnostics?

Mikolajczyk SD, Song Y, Wong JR, Matson RS, Rittenhouse HG.

Clin Biochem. 2004 Jul;37(7):519-28. Review.

PMID:
15234233
31.

Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.

Mikolajczyk SD, Rittenhouse HG.

Rinsho Byori. 2004 Mar;52(3):223-30. Review.

PMID:
15137320
32.

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM.

Urology. 2004 May;63(5):905-10; discussion 910-1.

PMID:
15134977
33.

Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness.

Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol MJ, Schröder FH.

J Urol. 2004 Jun;171(6 Pt 1):2245-9.

PMID:
15126795
34.

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, Klocker H, Mikolajczyk SD.

J Urol. 2004 Jun;171(6 Pt 1):2239-44.

PMID:
15126794
35.

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.

Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A, Rittenhouse HG.

Clin Chem. 2004 Jun;50(6):1017-25. Epub 2004 Mar 30.

PMID:
15054080
36.

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.

Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.

Urology. 2004 Mar;63(3):492-8.

PMID:
15028444
37.

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.

Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H, Mikolajczyk SD.

J Urol. 2003 Dec;170(6 Pt 1):2181-5.

PMID:
14634374
38.

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.

Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.

J Urol. 2003 Sep;170(3):723-6.

PMID:
12913682
39.
40.

Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.

Chan TY, Mikolajczyk SD, Lecksell K, Shue MJ, Rittenhouse HG, Partin AW, Epstein JI.

Urology. 2003 Jul;62(1):177-81.

PMID:
12837462
41.

Standardization of two immunoassays for human glandular kallikrein 2.

Haese A, Vaisanen V, Finlay JA, Pettersson K, Rittenhouse HG, Partin AW, Bruzek DJ, Sokoll LJ, Lilja H, Chan DW.

Clin Chem. 2003 Apr;49(4):601-10.

PMID:
12651813
42.

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.

Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, Mangold LA, Mohr P, Bartsch G, Klocker H, Horninger W, Partin AW.

Urology. 2003 Feb;61(2):274-6.

PMID:
12597929
43.

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.

Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD.

Clin Chem. 2003 Feb;49(2):253-9.

PMID:
12560348
44.

Free prostate-specific antigen in serum is becoming more complex.

Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG.

Urology. 2002 Jun;59(6):797-802. Review. No abstract available.

PMID:
12031356
45.

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.

Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA.

Urology. 2002 Jan;59(1):2-8. Review. No abstract available.

PMID:
11796270
46.

Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells.

Saedi MS, Zhu Z, Marker K, Liu RS, Carpenter PM, Rittenhouse H, Mikolajczyk SD.

Int J Cancer. 2001 Nov;94(4):558-63.

47.

A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.

Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P, Rittenhouse HG.

Cancer Res. 2001 Sep 15;61(18):6958-63.

48.

Development of a dual monoclonal antibody immunoassay for total human kallikrein 2.

Finlay JA, Day JR, Evans CL, Carlson R, Kuus-Reichel K, Millar LS, Mikolajczyk SD, Goodmanson M, Klee GG, Rittenhouse HG.

Clin Chem. 2001;47(7):1218-24.

PMID:
11427452
49.

Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia.

Mikolajczyk SD, Millar LS, Marker KM, Wang TJ, Rittenhouse HG, Marks LS, Slawin KM.

Prostate. 2000 Nov 1;45(3):271-6.

PMID:
11074531
50.

New nomenclature for the human tissue kallikrein gene family.

Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H.

Clin Chem. 2000 Nov;46(11):1855-8. No abstract available.

PMID:
11067830

Supplemental Content

Loading ...
Support Center